Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NK012 + carboplatin
- Development stage
- Phase 1
- Lead developer
- Nippon Kayaku
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
NK012 + carboplatin is a combination therapy under investigation for the treatment of solid tumors. NK012 is a polymeric micelle formulation containing SN-38, the active metabolite of irinotecan (CPT-11), which acts as a topoisomerase I inhibitor. Unlike CPT-11, NK012 releases SN-38 via hydrolysis and does not require metabolic conversion by enzymes. This allows for direct delivery of the active agent to tumor cells and may result in improved antitumor activity and reduced gastrointestinal toxicity compared to irinotecan[6]. Carboplatin is an organoplatinum alkylating agent that works by forming DNA crosslinks and monoadducts, thereby inhibiting DNA synthesis and transcription in cancer cells[1][4]. The combination aims to leverage both agents' mechanisms for enhanced efficacy against various solid tumors.
- Brand names
- Paraplatin
- Other names
- 7-ethyl-10-hydroxy-camptothecin polymeric micelleSN-38 polymeric micelleSN38 polymeric micelleSN 38 polymeric micelleCARBOplatin Novaplus
02
Targets
DNATOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on NK012 + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NK012 + carboplatin.